Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M506462200 on September 12, 2005 Originally published In Press as doi:10.1074/jbc.M506462200 on August 8, 2005

J. Biol. Chem., Vol. 280, Issue 44, 36784-36791, November 4, 2005
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
280/44/36784    most recent
M506462200v2
M506462200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lin, C.
Right arrow Articles by Kwong, A. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lin, C.
Right arrow Articles by Kwong, A. D.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

In Vitro Studies of Cross-resistance Mutations against Two Hepatitis C Virus Serine Protease Inhibitors, VX-950 and BILN 2061*

Chao Lin1, Cynthia A. Gates, B. Govinda Rao, Debra L. Brennan, John R. Fulghum, Yu-Ping Luong, J. Daniel Frantz, Kai Lin, Sue Ma, Yun-Yi Wei, Robert B. Perni, and Ann D. Kwong

From the Vertex Pharmaceuticals Incorporated, Cambridge, Massachusetts 02139

VX-950 is a potent, small molecule, peptidomimetic inhibitor of the hepatitis C virus (HCV) NS3·4A serine protease and has recently been shown to possess antiviral activity in a phase I trial in patients chronically infected with genotype 1 HCV. In a previous study, we described in vitro resistance mutations against either VX-950 or another HCV NS3·4A protease inhibitor, BILN 2061 (Lin, C., Lin, K., Luong, Y.-P., Rao, B. G., Wei, Y.-Y., Brennan, D. L., Fulghum, J. R., Hsiao, H.-M., Ma, S., Maxwell, J. P., Cottrell, K. M., Perni, R. B., Gates, C. A., and Kwong, A. D. (2004) J. Biol. Chem. 279, 17508-17514). Single amino acid substitutions that conferred drug resistance (distinct for either inhibitor) were identified in the HCV NS3 serine protease domain. The dominant VX-950-resistant mutant (A156S) remains sensitive to BILN 2061. The major BILN 2061-resistant mutants (D168V and D168A) are fully susceptible to VX-950. Modeling analysis suggested that there are different mechanisms of resistance for these mutations induced by VX-950 or BILN 2061. In this study, we identified mutants that are cross-resistant to both HCV protease inhibitors. The cross-resistance conferred by substitution of Ala156 with either Val or Thr was confirmed by characterization of the purified enzymes and reconstituted replicon cells containing the single amino acid substitution A156V or A156T. Both cross-resistance mutations (A156V and A156T) displayed significantly diminished fitness (or replication capacity) in a transient replicon cell system.

Received for publication, June 14, 2005 , and in revised form, July 20, 2005.

* The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 To whom correspondence should be addressed: Dept. of Infectious Diseases Biology, Vertex Pharmaceuticals Inc., 130 Waverly St., Cambridge, MA 02139. Tel.: 617-444-6202; Fax: 617-444-6210; E-mail: chao_lin{at}vrtx.com.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Therapeutic Advances in GastroenterologyHome page
J.-M. Pawlotsky
Review: Therapeutic implications of hepatitis C virus resistance to antiviral drugs
Therapeutic Advances in Gastroenterology, July 1, 2009; 2(4): 205 - 219.
[Abstract] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
S. T. Shi, K. J. Herlihy, J. P. Graham, J. Nonomiya, S. V. Rahavendran, H. Skor, R. Irvine, S. Binford, J. Tatlock, H. Li, et al.
Preclinical Characterization of PF-00868554, a Potent Nonnucleoside Inhibitor of the Hepatitis C Virus RNA-Dependent RNA Polymerase
Antimicrob. Agents Chemother., June 1, 2009; 53(6): 2544 - 2552.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
M. F. McCown, S. Rajyaguru, S. Kular, N. Cammack, and I. Najera
GT-1a or GT-1b Subtype-Specific Resistance Profiles for Hepatitis C Virus Inhibitors Telaprevir and HCV-796
Antimicrob. Agents Chemother., May 1, 2009; 53(5): 2129 - 2132.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
L. Coelmont, S. Kaptein, J. Paeshuyse, I. Vliegen, J.-M. Dumont, G. Vuagniaux, and J. Neyts
Debio 025, a Cyclophilin Binding Molecule, Is Highly Efficient in Clearing Hepatitis C Virus (HCV) Replicon-Containing Cells When Used Alone or in Combination with Specifically Targeted Antiviral Therapy for HCV (STAT-C) Inhibitors
Antimicrob. Agents Chemother., March 1, 2009; 53(3): 967 - 976.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
M. Flint, S. Mullen, A. M. Deatly, W. Chen, L. Z. Miller, R. Ralston, C. Broom, E. A. Emini, and A. Y. M. Howe
Selection and Characterization of Hepatitis C Virus Replicons Dually Resistant to the Polymerase and Protease Inhibitors HCV-796 and Boceprevir (SCH 503034)
Antimicrob. Agents Chemother., February 1, 2009; 53(2): 401 - 411.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
S. D. Seiwert, S. W. Andrews, Y. Jiang, V. Serebryany, H. Tan, K. Kossen, P. T. R. Rajagopalan, S. Misialek, S. K. Stevens, A. Stoycheva, et al.
Preclinical Characteristics of the Hepatitis C Virus NS3/4A Protease Inhibitor ITMN-191 (R7227)
Antimicrob. Agents Chemother., December 1, 2008; 52(12): 4432 - 4441.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
J. Paeshuyse, I. Vliegen, L. Coelmont, P. Leyssen, O. Tabarrini, P. Herdewijn, H. Mittendorfer, J. Easmon, V. Cecchetti, R. Bartenschlager, et al.
Comparative In Vitro Anti-Hepatitis C Virus Activities of a Selected Series of Polymerase, Protease, and Helicase Inhibitors
Antimicrob. Agents Chemother., September 1, 2008; 52(9): 3433 - 3437.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
M. F. McCown, S. Rajyaguru, S. Le Pogam, S. Ali, W.-R. Jiang, H. Kang, J. Symons, N. Cammack, and I. Najera
The Hepatitis C Virus Replicon Presents a Higher Barrier to Resistance to Nucleoside Analogs than to Nonnucleoside Polymerase or Protease Inhibitors
Antimicrob. Agents Chemother., May 1, 2008; 52(5): 1604 - 1612.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
D. L. Wyles, K. A. Kaihara, and R. T. Schooley
Synergy of a Hepatitis C Virus (HCV) NS4A Antagonist in Combination with HCV Protease and Polymerase Inhibitors
Antimicrob. Agents Chemother., May 1, 2008; 52(5): 1862 - 1864.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
Y. He, M. S. King, D. J. Kempf, L. Lu, H. B. Lim, P. Krishnan, W. Kati, T. Middleton, and A. Molla
Relative Replication Capacity and Selective Advantage Profiles of Protease Inhibitor-Resistant Hepatitis C Virus (HCV) NS3 Protease Mutants in the HCV Genotype 1b Replicon System
Antimicrob. Agents Chemother., March 1, 2008; 52(3): 1101 - 1110.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
G. Cheng, A. Montero, P. Gastaminza, C. Whitten-Bauer, S. F. Wieland, M. Isogawa, B. Fredericksen, S. Selvarajah, P. A. Gallay, M. R. Ghadiri, et al.
A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro
PNAS, February 26, 2008; 105(8): 3088 - 3093.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
S. T. Shi, K. J. Herlihy, J. P. Graham, S. A. Fuhrman, C. Doan, H. Parge, M. Hickey, J. Gao, X. Yu, F. Chau, et al.
In Vitro Resistance Study of AG-021541, a Novel Nonnucleoside Inhibitor of the Hepatitis C Virus RNA-Dependent RNA Polymerase
Antimicrob. Agents Chemother., February 1, 2008; 52(2): 675 - 683.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
Y. Zhou, D. J. Bartels, B. L. Hanzelka, U. Muh, Y. Wei, H.-M. Chu, A. M. Tigges, D. L. Brennan, B. G. Rao, L. Swenson, et al.
Phenotypic Characterization of Resistant Val36 Variants of Hepatitis C Virus NS3-4A Serine Protease
Antimicrob. Agents Chemother., January 1, 2008; 52(1): 110 - 120.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
R. K. F. Beran, V. Serebrov, and A. M. Pyle
The Serine Protease Domain of Hepatitis C Viral NS3 Activates RNA Helicase Activity by Promoting the Binding of RNA Substrate
J. Biol. Chem., November 30, 2007; 282(48): 34913 - 34920.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y. Zhou, U. Muh, B. L. Hanzelka, D. J. Bartels, Y. Wei, B. G. Rao, D. L. Brennan, A. M. Tigges, L. Swenson, A. D. Kwong, et al.
Phenotypic and Structural Analyses of Hepatitis C Virus NS3 Protease Arg155 Variants: SENSITIVITY TO TELAPREVIR (VX-950) AND INTERFERON {alpha}
J. Biol. Chem., August 3, 2007; 282(31): 22619 - 22628.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
D. L. Wyles, K. A. Kaihara, F. Vaida, and R. T. Schooley
Synergy of Small Molecular Inhibitors of Hepatitis C Virus Replication Directed at Multiple Viral Targets
J. Virol., March 15, 2007; 81(6): 3005 - 3008.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
A. Wohnsland, W. P. Hofmann, and C. Sarrazin
Viral Determinants of Resistance to Treatment in Patients with Hepatitis C
Clin. Microbiol. Rev., January 1, 2007; 20(1): 23 - 38.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
R. Liu, K. Abid, J. Pichardo, V. Pazienza, P. Ingravallo, R. Kong, S. Agrawal, S. Bogen, A. Saksena, K.-C. Cheng, et al.
In vitro antiviral activity of SCH446211 (SCH6), a novel inhibitor of the hepatitis C virus NS3 serine protease
J. Antimicrob. Chemother., January 1, 2007; 59(1): 51 - 58.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
H. Dutartre, C. Bussetta, J. Boretto, and B. Canard
General Catalytic Deficiency of Hepatitis C Virus RNA Polymerase with an S282T Mutation and Mutually Exclusive Resistance towards 2'-Modified Nucleotide Analogues
Antimicrob. Agents Chemother., December 1, 2006; 50(12): 4161 - 4169.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
K. Lin, R. B. Perni, A. D. Kwong, and C. Lin
VX-950, a Novel Hepatitis C Virus (HCV) NS3-4A Protease Inhibitor, Exhibits Potent Antiviral Activities in HCV Replicon Cells.
Antimicrob. Agents Chemother., May 1, 2006; 50(5): 1813 - 1822.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
R. B. Perni, S. J. Almquist, R. A. Byrn, G. Chandorkar, P. R. Chaturvedi, L. F. Courtney, C. J. Decker, K. Dinehart, C. A. Gates, S. L. Harbeson, et al.
Preclinical Profile of VX-950, a Potent, Selective, and Orally Bioavailable Inhibitor of Hepatitis C Virus NS3-4A Serine Protease
Antimicrob. Agents Chemother., March 1, 2006; 50(3): 899 - 909.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2005 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement